Skip to content

PTHS PTHS Xepi Royalty Agreement — Interest accretion

Similar metrics at other companies

Theravance Biopharma logo
TBPHInterest Accretion On Future Royalty Payment Contingencies
$582K-9.5%
PVL
PVLANoncash Interest Expense Income Royalty Agreement
$2.04M+67.8%
Omeros logo
OMERNon Cash Interest Expense On Royalty Obligation
-$1.41M+58.2%
BridgeBio Pharma logo
BBIONoncash interest expense on deferred royalty obligations
$39.87M+66.0%
AnaptysBio, Inc. logo
ANABNoncash Advance Future Royalties Interest Expense
$20.86M+15.5%
XOMA Corporation logo
XOMAIxinity — Income Not From Contract With Customer Effective Interest Rate Method
$246K-2.8%

Other financials

Income statement

See full
Revenue$10.9M
Gross profit$9.2M
Operating income-$13.1M-614%
Net income-$10.2M-420%
EPS (diluted)-$3.09+3.7%

Balance sheet

See full
Cash & equivalents$32.0M+24,250%
Total debt$29.6M
Total equity$35.1M+937%
Total assets$145.4M+15,855%

Cash flow

See full
Operating cash flow-$13.1M-1,977%
CapEx$194.0K
Free cash flow-$13.3M-2,008%

Valuation

See full
Market cap$98.22M+75.4%
Enterprise value$95.89M
P/S3.6×

Profitability

See full
Gross margin79.6%
Operating margin-157.7%
Net margin-186.2%
FCF margin-60.8%

Returns & leverage

See full
Return on equity-333.8%
Debt / equity0.8×
Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept pths:ContractualObligationLiabilityInterestAccretion.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's xepi royalty agreement — interest accretion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTHS's xepi royalty agreement — interest accretion?
PTHS (PTHS) reported xepi royalty agreement — interest accretion of $55K in Q1 2026.
What does xepi royalty agreement — interest accretion mean?
The non-cash interest expense recognized over time to adjust the carrying value of the Xepi royalty liability toward its ultimate settlement amount. This reflects the financing cost inherent in the structure of the long-term royalty obligation.